MiNK Therapeutics (NASDAQ:INKT) Posts Earnings Results, Misses Expectations By $0.02 EPS

MiNK Therapeutics (NASDAQ:INKT) issued its quarterly earnings data on Thursday. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.02), Zacks reports.

Here are the key takeaways from MiNK Therapeutics’ conference call:

• MiNK advanced agenT-797 into a randomized Phase II ARDS study, with enrollment continuing in Ukraine and U.S. sites expected to begin enrolling in September. The company expects preliminary randomized data in the first half of 2027 and is preparing to discuss a potential seamless Phase III design with the FDA.
• Initial observations from two treated patients showed survival without fever at day 28, improved oxygenation, ARDS resolution, spontaneous breathing, vasopressor liberation, infection control, and no major treatment-related serious adverse events. However, management emphasized that the data are early, non-comparative, and based on a small run-in cohort.
• MiNK launched its first international paid named-patient access program in Brazil, generating physician-directed access and payments while building cross-border logistics and regulatory infrastructure. The company said additional patients were treated after quarter-end and that further financial details are expected with its third-quarter update.
• MiNK ended the quarter with $8.8 million in cash, down from $9.5 million at the end of the first quarter, while quarterly operating cash use increased to $2.1 million as the Phase II trial was operationalized. The company continues to report losses and did not provide explicit cash-runway guidance.

MiNK Therapeutics Trading Up 1.5%

NASDAQ INKT traded up $0.16 on Friday, hitting $11.16. 4,300 shares of the company traded hands, compared to its average volume of 134,234. The business’s 50 day moving average price is $11.34 and its 200-day moving average price is $11.23. MiNK Therapeutics has a 52-week low of $8.48 and a 52-week high of $18.17. The company has a market capitalization of $55.58 million, a price-to-earnings ratio of -3.93 and a beta of 0.48.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the stock. HC Wainwright reiterated a “buy” rating and set a $35.00 target price on shares of MiNK Therapeutics in a research note on Monday, May 18th. Wall Street Zen raised MiNK Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Zacks Research cut MiNK Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday. Finally, Weiss Ratings upgraded MiNK Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, July 6th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, MiNK Therapeutics currently has an average rating of “Hold” and a consensus target price of $35.00.

MiNK Therapeutics News Roundup

Here are the key news stories impacting MiNK Therapeutics this week:

• Positive Sentiment: MiNK said U.S. enrollment in its acute respiratory distress syndrome (ARDS) study is expected to begin in September, with an estimated enrollment pace of four to eight patients per site each month. The timeline and projected recruitment rate could accelerate clinical development and improve visibility for agenT-797. MiNK outlines 4-8 patients per site per month as U.S. ARDS enrollment starts in September
• Positive Sentiment: Management highlighted early promise from agenT-797 in the randomized Phase 2 acute lung injury program. Positive observations in this high-need indication could provide an important catalyst for the small-cap biotechnology company, although the data remain early-stage and require further validation. MiNK Therapeutics Q2 2026 Earnings Call Highlights
• Neutral Sentiment: MiNK reported second-quarter 2026 results and reiterated its focus on off-the-shelf allogeneic iNKT-cell therapies for cancer and immune disorders. The earnings call provided additional program updates, but the company remains clinical-stage and does not yet have product revenue. MiNK Therapeutics Q2 2026 Earnings Call Summary
• Negative Sentiment: MiNK posted a loss of $0.62 per share for the quarter, missing the $0.60-per-share consensus estimate. Continued losses and the absence of commercial revenue underscore the company’s financing and execution risks. MiNK Therapeutics quarterly earnings results
• Negative Sentiment: Zacks Research downgraded MiNK from “strong-buy” to “hold,” potentially weakening near-term sentiment and reducing support from analyst recommendations. Zacks Research

Institutional Inflows and Outflows

An institutional investor recently raised its position in MiNK Therapeutics stock. Geode Capital Management LLC lifted its stake in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) by 11.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 14,247 shares of the company’s stock after acquiring an additional 1,441 shares during the quarter. Geode Capital Management LLC owned approximately 0.30% of MiNK Therapeutics worth $159,000 at the end of the most recent reporting period. Institutional investors own 2.87% of the company’s stock.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.